Clinical Trial

Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel design phase II clinical trial, including a screening period of up to 2 weeks, a 36-weeks' treatment period, and a 1-week safety follow-up visit period.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-06; most recent amendment 2025-12-19.
Status change: Not Yet Recruiting → Recruiting 2025-04-22
Trial Details
NCT Number NCT06820099
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Enrollment 225 participants
Start Date 2025-04-10
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-29